News

According to the company, the Denali trial is evaluating NCX 470 safety and efficacy in patients with open-angle glaucoma or ocular hypertension and topline results continue to be expected in H2 2025

According to the company, OCU410 utilizes an adeno-associated virus platform for the retinal delivery of the RORA gene.

Therapeutics can prevent vision loss and neurodegeneration in patients.

The organization is poised to lobby for an indefinite extension of Medicare reimbursement for telemedicine services and fight the December 31, 2024, sunset date when Medicare plans to cease reimbursement for these services.

Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.

At this year's ASRS meeting, Sally S. Ong, MD, shared results from a 10-year study on socioeconomic barriers and visual outcomes

The organization is poised to lobby for an indefinite extension of Medicare reimbursement for telemedicine services and fight the December 31, 2024, sunset date when Medicare plans to cease reimbursement for these services.

Sally S. Ong, MD, spoke about her study on the impact of individual and neighborhood-level social determinants of health on vision and foveal status at presentation in patients with rhegmatogenous retinal detachments at the annual ASRS meeting in Stockholm, Sweden.

The nOCT allows for detailed visualization of the brain's vascular anatomy.

The collaboration agreement will allow the 2 companies to find a potential new treatment for chronic dry eye disease.

John T. Thompson, MD, spoke about his presentation, "Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling" at the annual ASRS meeting in Stockholm, Sweden.

Funding for the device was thanks to companies like Nike and the Oregon ToughTech Breakthrough Fund.

Early diagnosis of NMOSD is key to preventing disability, improving survival.

Yasha Modi, MD, spoke with Modern Retina about the ASRS 2024: The DAVIO phase 2 trial and upcoming LUGANO phase 3 trial at the annual ASRS meeting in Stockholm, Sweden.

Ashkan Abbey, MD, discusses 36-month outcomes of real-world patients receiving fluocinolone acetonide 0.18 mg

According to the company, the tuck-in acquisition will help expand its surgical presence in the United States and contribute to its leading position in dry eye.

Michael Singer, MD, presented 100-week results from the RESTORE trial and shares key takeaways from his presentation at this year's American Society of Retina Specialists (ASRS) meeting.

Nikoloz Labauri, MD, FVRS, speaks about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy at ASRS 2024

Jordana Fein, MD, MS, speaks about intraocular pressure outcomes in patients receiving aflibercept through week 48 of the PHOTON trial

A recent study found that adolescents with myopia were twice as likely to develop anxiety and mood disorders.

Patrick C. Staropoli, MD, discussed his presentation on the clinical characterization of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa while attending the annual ASRS meeting in Stockholm, Sweden.

The nOCT allows for detailed visualization of the brain's vascular anatomy.

TFI employs spectral interference technology to image and map the corneal surface.

Jordana Fein, MD, MS, spoke with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.

Riaz Qureshi, PhD, explains the effects of spin sneaking into systematic reviews and ways the scientific community can better identify it to improve the validity.

Stephen Russell, MD, discussed his presentation on safety and durability of voretigene neparvovec-rzyl for biallelic RPE65 at the annual ASRS meeting in Stockholm, Sweden.

Charles Wykoff, MD, PhD, gives an insight into first-time data from the phase 2, LUNA trial looking at Ixo-Vec at the annual ASRS meeting in Stockholm, Sweden.

Researchers train deep learning model on OCT scans to ID patients eligible for GA trials.